20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for improved solubility of APIs and extended release. Validated as an eye drop, we have successful pre-clinical studies in glaucoma, dry eye and uveitis.
20/20 OptimEyes Technologies is seeking partners to further develop ophthalmic assets or those with novel or repurposed APIs for co-development opportunities in humans and companion animals. The company is also looking for partners with assets targeting other mucosal areas (nasal, optic, buccal, vaginal or GI).
Intellectual Property
Fundraising
The Synapse Life Science Competition combines the ideas and research of life science innovators with the intellect and strategy of students. Finalists receive training, mentorship, a $2,000 grant and a chance to pitch and compete for BIG cash prizes!
Applications close on November 10, 2024.